Literature DB >> 6810779

Cardiovascular effects of GABA, GABA-aminotransferase inhibitors and valproic acid following systemic administration in rats, cats and dogs: pharmacological approach to localize the site of action.

W Löscher.   

Abstract

The cardiovascular effects of GABA, sodium valproate (VPA) and inhibitors of GABA-aminotransferase (GABA-T), namely aminooxyacetic acid, gabaculine, gamma-acetylenic GABA, gamma-vinyl GABA and ethanolamine-O-sulphate (EOS), were studied in anesthetized rats, cats and dogs. All compounds were administered intravenously in dose levels previously shown as anticonvulsant active. In rats and cats, GABA (100-1000 mg/kg) caused a sustained fall of blood pressure and heart rate. A similar reaction was observed in dogs following maintenance infusion of the amino acid. The prolonged cardiovascular depression in response to GABA could be attenuated by subsequent administration of picrotoxin and bicuculline as well as by alpha-methyltyrosine, corynanthine, chlorpromazine and tripelennamine. Phentolamine, yohimbine, propranolol, vagotomy, atropine, cyproheptadine, apomorphine and haloperidol did not antagonize the cardiovascular effects of GABA. Administration of GABA-T inhibitors provoked prolonged hypotension and bradycardia, which could be partially counteracted by picrotoxin, bicuculline and, except in the case of EOS, by chlorpromazine. VPA, in high doses (300-400 mg/kg) exerted similar cardiovascular effects in rats as observed with GABA and GABA-T inhibitors. The prolonged cardiovascular depression caused by VPA could be counteracted by bicuculline and partially by chlorpromazine. Apomorphine led to a considerable potentiation of the effects of VPA. It is concluded that GABA, GABA-T inhibitors and VPA may induce cardiovascular depression at least in part by activation of GABA receptors and that the response is mediated predominantly by the central adrenergic system. Some indication was found that an interaction with peripheral histamine contributes to the cardiovascular effects of GABA.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6810779

Source DB:  PubMed          Journal:  Arch Int Pharmacodyn Ther        ISSN: 0003-9780


  8 in total

1.  Effects of gamma-vinyl GABA (vigabatrin) on blood pressure and body weight of hypertensive and normotensive rats.

Authors:  N Singewald; A Pfitscher; A Philippu
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-02       Impact factor: 3.000

2.  Developmental changes in expression of GABAA receptor-channels in rat intrinsic cardiac ganglion neurones.

Authors:  Harald Fischer; Alexander A Harper; Colin R Anderson; David J Adams
Journal:  J Physiol       Date:  2005-02-24       Impact factor: 5.182

3.  Age-dependent changes in cardiovascular responses induced by muscimol infused into the nucleus tractus solitarii and nucleus parabrachialis medialis in rats.

Authors:  V Mollace; E A De Francesco; G Fersini; G Nistico
Journal:  Br J Pharmacol       Date:  1991-07       Impact factor: 8.739

4.  The GABA/benzodiazepine receptor complex in the nervous system of a hypertensive strain of rat.

Authors:  G Tunnicliff; K L Welborn; R A Head
Journal:  Neurochem Res       Date:  1984-08       Impact factor: 3.996

5.  Valproate treatment and cocaine cue reactivity in cocaine dependent individuals.

Authors:  Malcolm S Reid; Vatsal Thakkar
Journal:  Drug Alcohol Depend       Date:  2009-04-16       Impact factor: 4.492

6.  The involvement of GABA-transaminase in the blood-brain barrier to radiolabelled GABA.

Authors:  A Krantis
Journal:  Acta Neuropathol       Date:  1984       Impact factor: 17.088

Review 7.  gamma-Aminobutyric acid and cardiovascular function.

Authors:  F V DeFeudis
Journal:  Experientia       Date:  1983-08-15

8.  Sodium valproate stimulates potassium and chloride urinary excretion in rats: gender differences.

Authors:  Eitaute Jakutiene; Jurgita Grikiniene; Arunas Vaitkevicius; Marina Tschaika; Janina Didziapetriene; Donatas Stakisaitis
Journal:  BMC Pharmacol       Date:  2007-08-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.